HomeAI · summaries
Storia in 3 fonti
The Potential Havoc Of Generic Drug Tariffs
In this week’s edition of InnovationRx, we look at the companies looking to cash in on the coming peptide bonanza, the ongoing cyclosporiasis outbreak, Tempus’s acquisition of a cancer-testing company, and more.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
The Potential Havoc Of Generic Drug Tariffs
In this week’s edition of InnovationRx, we look at the companies looking to cash in on the coming peptide bonanza, the ongoing cyclosporiasis outbreak, Tempus’s acquisition of a…
- ·
zerohedge.com
UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring Winners
"For our generics coverage, we view the group as relatively well-positioned given: AMRX (significant US infrastructure), TEVA..."
- ·
fiercepharma.com
Trump floats countdown to 200% tariffs on generic drugs imported to US
While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the vast majority of U.S. | While the White House focused…